Skip to main content

Advertisement

Log in

Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the impact of concomitant carcinoma in situ (CIS) on upstaging and outcome of patients treated with radical cystectomy with pelvic lymph node dissection.

Methods

We collected and pooled a database of 1,968 patients who have undergone radical cystectomy between 1998 and 2008 in eight academic centers across Canada. Collected variables included patient’s age, gender, tumor grade, histology and the presence of concomitant CIS with either cTa-1 or cT2 disease, dates of recurrence and death.

Results

In the presence of concomitant CIS, upstaging following radical cystectomy occurred in 48 and 55 % of patients with cTa-1 and cT2 disease, respectively. On univariate analysis, the presence of concomitant CIS with cT2 disease was associated with upstaging (p < 0.0001), and the presence of concomitant CIS with cTa-1 disease was also associated with upstaging but did not reach statistical significance (p = 0.0526). On multivariate analyses, the presence of concomitant CIS with either cTa-1 or cT2 tumors was independently prognostic of disease upstaging (p = 0.0001 and 0.0186, respectively). However, on multivariate analysis that incorporates pathologic stage, concomitant CIS was not significantly associated with worse overall, recurrence-free or disease-specific survival.

Conclusion

These results demonstrate that while the presence of concomitant CIS on cystectomy specimens does not independently affect outcomes, its presence is significantly predictive of a higher rate of upstaging at radical cystectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  2. Heney NM (1992) Natural history of superficial bladder cancer. Prognostic factors and long-term disease course. Urol Clin North Am 19:429–433

    PubMed  CAS  Google Scholar 

  3. Kassouf W, Kamat AM, Zlotta A et al (2010) Canadian guidelines for treatment of non-muscle invasive bladder cancer-a focus on intravesical therapy. Can Urol Assoc J 4:168–173

    Article  PubMed  PubMed Central  Google Scholar 

  4. van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500

    Article  PubMed  Google Scholar 

  5. Murphy WM, Takezawa K, Maruniak NA (2002) Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms: practical choices for patient care. J Urol 168:968–972

    Article  PubMed  Google Scholar 

  6. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466

    Article  Google Scholar 

  7. Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309

    Article  PubMed  Google Scholar 

  8. Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59

    Article  PubMed  CAS  Google Scholar 

  9. Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W-F, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152

    Article  PubMed  Google Scholar 

  10. Cheng L, Neumann RM, Weaver AL et al (2000) Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113:275–279

    Article  PubMed  CAS  Google Scholar 

  11. Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95:786–790

    Article  PubMed  Google Scholar 

  12. Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31–36

    PubMed  CAS  Google Scholar 

  13. Freeman JA, Esrig D, Stein JP et al (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76:833–839

    Article  PubMed  CAS  Google Scholar 

  14. Masood S, Sriprasad S, Palmer JH, Mufti GR (2004) T1G3 bladder cancer—indications for early cystectomy. Int Urol Nephrol 36:41–44

    Article  PubMed  CAS  Google Scholar 

  15. Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior SW, Thuroff JW (2005) Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95:301–305

    Article  PubMed  Google Scholar 

  16. Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493

    Article  PubMed  CAS  Google Scholar 

  17. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75

    Article  PubMed  Google Scholar 

  18. Gupta A, Lotan Y, Bastian P et al (2008) Outcomes of patients with clinical T1 Grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71:302–307

    Article  PubMed  Google Scholar 

  19. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  PubMed  CAS  Google Scholar 

  20. Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer: nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425

    Article  PubMed  CAS  Google Scholar 

  21. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540

    Article  Google Scholar 

  22. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177

    Google Scholar 

  23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205

    Article  Google Scholar 

  24. Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422

    Article  PubMed  Google Scholar 

  25. Nuhn P, Bastian PJ, Novara G et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42–48

    Article  PubMed  Google Scholar 

  26. Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today- a homogeneous series without neoadjuvant therapy. J Clin Oncol 4:690–696

    Article  Google Scholar 

  27. Ghoneim MA, Abdel-Latif M, El-Mekresh M et al (2008) Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 180:121–127

    Article  PubMed  Google Scholar 

  28. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675

    PubMed  CAS  Google Scholar 

  29. Dalbagni G, Genega E, Hashibe M et al (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165:1111–1116

    Article  PubMed  CAS  Google Scholar 

  30. Yafi FA, Aprikian AG, Chin JL et al (2011) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 108:539–545

    Article  PubMed  Google Scholar 

  31. Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Faysal A. Yafi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yafi, F.A., Aprikian, A.G., Chin, J.L. et al. Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32, 1295–1301 (2014). https://doi.org/10.1007/s00345-013-1207-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-013-1207-z

Keywords

Navigation